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Abstract
The status of serotonin 5HT2A receptors (5HT2ARs) in schizophrenia has been controversial. In vivo positron emission
tomography neuroimaging and in vitro post-mortem binding studies have reported conflicting results about 5HT2AR
density. Radiotracers bind different receptor conformations depending on their agonist, antagonist or inverse agonist
properties. This study investigates 5HT2AR density in the post-mortem prefrontal cortex from subjects with
schizophrenia and controls using three radiotracers with a different pharmacological profile. The specific binding
parameters of the inverse agonist [18F]altanserin, the agonist [3H]lysergic acid diethylamide (LSD) and the antagonist
[3H]MDL100907 to brain cortex membranes from 20 subjects with schizophrenia and 20 individually matched controls
were evaluated under similar methodological conditions. Ten schizophrenia subjects were antipsychotic-free at death.
Saturation curve analyses were performed by non-linear regression to obtain a maximal density of binding sites (Bmax)
and the affinity of the respective radiotracers (Kd). In schizophrenia subjects, 5-HT2AR density was decreased when
quantified by [18F]altanserin binding, whereas increased when evaluated by [3H]LSD binding. However, [3H]
MDL100907 binding was unaltered. A slight loss of affinity (higher Kd) was observed exclusively in [
3H]LSD binding. The
findings were more evident in antipsychotic-free subjects than in antipsychotic-treated subjects. In conclusion, a
higher proportion of the 5-HT2AR-active functional conformation, which is rather identified by agonist radiotracers, was
observed in schizophrenia patients. A consequent reduction of the inactive 5-HT2AR conformation, which is
preferentially identified by inverse agonist radiotracers, was also obtained. Antagonist radiotracers do not distinguish
between molecular conformations of the receptor, and accordingly, the absence of changes was shown. These results
are compatible with the proposed increased functional activity of brain cortical 5-HT2ARs in schizophrenia.
Introduction
A role for serotonin (5-HT) in the pathophysiology and
therapeutics of schizophrenia is supported by converging
observations1. First, similarities between psychotic states
in psychiatric disorders and the effects of lysergic acid
diethylamide (LSD) and other 5-HT receptor-mediated
psychedelic drugs (e.g., mescaline and psilocybin) have
been described2. Second, cortical serotonin 5HT2A
receptors (5-HT2ARs) seem to be the critical target to
induce these psychosis-like responses3, and second-
generation antipsychotics such as clozapine, risperidone
and olanzapine, among others, display potent antagonism
properties on 5-HT2ARs. Furthermore, since 5-HT plays a
key role in emotional processing, it has been proposed
that dysregulation of 5-HT neurotransmission could
underlie the negative symptoms of schizophrenia1. The
5-HT receptor brain density is typically assessed in vivo
using positron emission tomography (PET)4 and in vitro
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using post-mortem tissue homogenates and sections (for
a review, see Supplementary Table S1). Evidence shows a
lower density of 5-HT2ARs in the frontal cortex of anti-
psychotic-naive schizophrenic patients when evaluated
with the very selective (200- to 500-fold higher affinity for
5-HT2ARs vs. dopamine D2 receptors (D2Rs)) radiotracer
[18F]altanserin5–7. In contrast, inconclusive results were
obtained with other radiotracers such as [18F]setoperone
and [18F]N-methyl spiperone8–11, which have 10- to 25-
fold 5-HT2AR selectivity vs. dopamine D2Rs
7. Since D2Rs
are clearly involved in schizophrenia pathophysiology and
treatment, the use of these radiotracers with substantial
D2R affinity is considered a source of bias for 5-HT2AR
detection. On the other hand, important differences
among studies have also been obtained from in vitro post-
mortem studies in the brain of subjects with schizo-
phrenia1,3,12. Thus, while some studies described up-
regulation of 5HT2ARs, others pointed towards the
absence of alterations or even a down-regulation in the
number of binding sites. These apparent discrepancies
among post-mortem studies have been considered in the
context of different demographic and clinical parameters,
the existence of diverse pharmacological treatments and
the variety of methodological approaches3,12–14. More-
over, as drug-free populations are difficult to obtain for
post-mortem studies, the existence of long-term anti-
psychotic treatment has been considered the main
explanatory factor for differences between in vivo neu-
roimaging studies in drug-naive patients and in vitro
findings in post-mortem brain. However, less attention
has been paid to the pharmacological properties, such as
agonist, antagonist or inverse agonist, of the respective
drugs used as radiotracer tools to identify 5HT2ARs. The
most common 5HT2AR drugs used to generate radi-
oligands for in vivo PET studies ([18F]altanserin and [11C]
M100907) are considered antagonists, and the efforts
towards the development of agonist radiotracers have
reported limited success15. In marked contrast, post-
mortem studies of 5HT2AR quantitation in schizophrenia
have been performed with the agonist [3H]LSD and the
partial agonist [3H]ketanserin radiotracers (Supplemen-
tary Table S1). Although unattended, the pharmacological
properties, such as agonist, antagonist or inverse agonist,
are determinants for the receptor conformation identified
by the radiotracer and, subsequently, for the estimated
binding density16.
G-protein-coupled receptors (GPCRs) and, among
them, 5HT2ARs display different molecular conformations
that are interchangeable and stay in equilibrium17. Thus,
the receptor conformation that couples to G proteins is
considered to be functionally active and represents the
high-affinity state of the receptor, which is preferentially
identified by agonist radioligands. Conversely, inverse
agonist radioligands show preference to bind the low-
affinity state, i.e., the inactive receptor conformation,
which is uncoupled from G proteins. Finally, antagonist
radioligands bind with similar affinity to both receptor
conformations (Fig. 1). Therefore, the binding of agonist
radioligands to the G-protein-coupled conformation
should serve as a more accurate measure of 5HT2AR
functions and dysfunctions than antagonist binding18,19.
In vitro studies have revealed increased functional cou-
pling of 5HT2ARs to G proteins in the brain cortex of
subjects with schizophrenia without alterations in total
values of receptor density20. This finding suggests that an
imbalance of 5HT2ARs towards the high-affinity receptor
conformation might be present in schizophrenia, leading
to overactive G-protein-dependent signalling. Under this
5HT2AR overactivity, enhanced agonist radioligand bind-
ing should be expected. Conversely, a decreased binding
of inverse agonist radioligands to the uncoupled con-
formation might indicate a decrease of the low-affinity
receptor state and prove the existence of an imbalance
between coupled and uncoupled 5HT2AR conformations
in schizophrenia, with receptor equilibrium displaced
towards the active conformational state (Fig. 2).
Although [18F]altanserin and [11C]MDL100907 were
initially developed as selective antagonist radiotracers to
quantify 5HT2ARs in PET studies
15, altanserin has
recently been demonstrated to show inverse agonist
Agonist / [3H]LSD
Antagonist / [3H]M100907
Inverse agonist / [18F]altanserin
Fig. 1 Conformational states of the 5-HT2AR. The receptor conformation coupled to G-protein signalling pathways represents the functional state
and is preferentially identified by agonist radioligands such as [3H]LSD. The inactive conformation of the 5-HT2AR, which is uncoupled from G
proteins, is preferentially labelled by inverse agonist radioligands such as [18F]altanserin. Active and inactive conformations are interchangeable states
that stay in equilibrium17. Antagonist radioligands, such as [3H]MDL100907, bind both receptor conformations and, therefore, do not distinguish
between functional and non-functional states.
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properties on 5HT2ARs in post-mortem human brain
13,21.
In fact, [18F]altanserin binding is decreased in the brain of
patients with schizophrenia5,6 and in prodromal at-risk
state subjects22. In contrast to PET evaluations, studies in
post-mortem brain of subjects with schizophrenia have
mainly been performed with the agonist [3H]LSD and the
partial agonist [3H]ketanserin radiotracers (Supplemen-
tary Table S1). Noticeably, among post-mortem studies,
those developed in antipsychotic-free schizophrenia cases
displayed enhanced 5HT2AR density in the prefrontal
cortex13,23,24. Based on all these observations, it could be
hypothesized that 5HT2AR agonists and inverse agonists
identify different molecular conformations of this recep-
tor in schizophrenia, leading to opposite findings. How-
ever, the 5HT2AR receptor binding of agonist, antagonist
and inverse agonist radiotracers has never been tested
under the same methodological conditions.
The aim of the present study was to investigate the
5HT2AR density in post-mortem prefrontal cortex of
subjects with schizophrenia, using three different radio-
tracers with different intrinsic activity properties (agonist,
antagonist and inverse agonist) on this receptor. [3H]LSD,
[3H]MDL100907 and [18F]altanserin were selected as
representative radiotracers with well-established phar-
macological profiles. LSD is a hallucinogenic drug with
5HT2AR partial agonist properties
25,26, and its 3H-labelled
form identifies this receptor under blocking conditions for
other 5-HT receptors. MDL100907 is a very selective 5-
HT2AR antagonist
27, whose 18F- and 11C-labelled forms
have been used for PET studies15,28. Altanserin is a highly
selective 5HT2AR inverse agonist
21, commonly considered
as antagonist PET radiotracer when labelled with 18F15.
The three radiotracers were evaluated on saturation
binding experiments in brain cortex membrane homo-
genates of the same subjects and under similar experi-
mental conditions. We sought to test the hypothesis that
different alterations of 5HT2AR density are obtained in
schizophrenia depending on the intrinsic activity prop-
erties of each radiotracer. The results would shed light on
the unclarified status of brain 5HT2ARs in schizophrenia.
Subjects, materials and methods
Post-mortem human brain samples
Brain samples were obtained at autopsies performed in
the Basque Institute of Legal Medicine, Bilbao, Spain, in
compliance with policies of research and ethical boards
for post-mortem brain studies. Deaths were subjected to
retrospective searching for previous medical diagnosis
and treatment using the examiner’s information and
records from hospitals and mental health centres. A total
number of 20 brains from subjects with ante-mortem
diagnosis of schizophrenia according to the Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV,
DSM-IV-TR) were matched to 20 brains from control
subjects in a paired design. Control subjects were chosen
among the collected brains on the basis of the absence of
neuropsychiatric disorders or drug abuse, and an appro-
priate sex, storage time and post-mortem interval (elapsed
time between death and tissue dissection/freezing) to
match each schizophrenia subject. Toxicological screen-
ing of blood samples of all subjects was performed to
determine the presence at death of antipsychotics, other
drugs and ethanol. According to the absence or presence
of antipsychotic drugs in this toxicological screening,
schizophrenia population was divided into two groups, a
group of antipsychotic-free (n= 10) and a group of
antipsychotic-treated (n= 10) subjects. Schizophrenia
and control groups were similar for sex ratio, age, storage
time and post-mortem interval values (Supplementary
Table S2). Seventeen out of the 20 subjects in the schi-
zophrenia group committed suicide. Matched control
subjects mainly died by accidental causes. Therefore, the
mechanism of death indicates that almost all were violent
or sudden. Specimens of the dorsolateral prefrontal cortex
(Brodmann’s area 9) were dissected at autopsy following
standard procedures and immediately stored at −80 °C
until assayed. A complete description of the whole
population of subjects with schizophrenia and their
individually matched controls can be found in Supple-
mentary Table S2. Some of the schizophrenia cases and





Fig. 2 Representation of the imbalance between 5-HT2AR
conformations towards the state preferentially labelled by
agonists observed in the prefrontal cortex of subjects with
schizophrenia. The disequilibrium promotes a G-protein
overactivation in response to 5-HT2AR agonists
20. Based on this
hypothesis, agonist radioligands should identify higher binding sites
and inverse agonist radioligands should label lower binding sites in
schizophrenia than in controls. Antagonist radioligands would not
discriminate between schizophrenia and control subjects.
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ketanserin binding density13,24 and G-protein activation
mediated by 5-HT2ARs
20,29 (see Supplementary Table S2
for details). The prefrontal cortex was selected as the
region of interest based on the morphological alterations
associated to schizophrenia30 and the large expression of
5-HT2ARs in the area
5.
Materials and drugs
MDL100907 (volinanserin) and altanserin were pur-
chased from Sigma-Aldrich. [3H]LSD (86.3 Ci/mmol at
delivery time) was obtained from PerkinElmer Life and
Analytical Sciences, Inc., and [3H]MDL100907 (80 Ci/
mmol at delivery time) was obtained from ARC Radio-
chemicals. All other chemicals were obtained from stan-
dard sources.
Synthesis of [18F]altanserin
[18F]altanserin was produced in a TRACERlab FXFN
synthesis module (GE Healthcare) by radiofluorination of
nitro-altanserin (ABX, Radeberg, Germany) as previously
published31. Specific activity at initial incubation time (see
below) was in the range 300–700 GBq/μmol. The average
radiochemical yield was 11 ± 4% (end of synthesis).
Radiochemical purity was >97% in all cases.
Brain membranes preparation
Brain cortex samples were processed to obtain
membrane-enriched homogenates as previously described13.
[18F]Altanserin, [3H]LSD and [3H]MDL100907 binding
assays
Complete saturation binding assays were performed
with [18F]altanserin (0.03–4 nM, eight concentrations),
[3H]LSD (0.03–10 nM, ten concentrations) and [3H]
MDL100907 (0.007–4 nM, ten concentrations) in order to
determine the density (Bmax) and the affinity (Kd) of 5-
HT2ARs. Incubation was carried out in tubes ([
18F]altan-
serin) or 96-well plates ([3H]LSD and [3H]MDL100907)
and started with the addition of the brain membrane
preparation. Reactions were incubated for 40min at 37 °C
for [18F]altanserin binding assays and 90min at 37 °C for
[3H]LSD and [3H]MDL100907 binding assays. The pre-
sence of MDL100907 (1 µM) or altanserin (10 µM) was
used to determine the non-specific binding of [18F]altan-
serin and [3H]LSD, and of [3H]MDL100907, respectively.
After incubation, free radioligand was separated from
bound radioligand by rapid filtration under vacuum
through GF/C glass fibre filters pre-soaked with 0.5%
polyethylenimine and counted for radioactivity gamma
counting ([18F]altanserin; 2470 WIZARD2 Automatic
Gamma Counter, PerkinElmer) or by liquid scintillation
([3H]LSD and [3H]MDL100907; MicroBeta TriLux
Counter, PerkinElmer). Results were corrected for each
radiotracer decay. Pairs of cases and controls were always
processed at the same time and all samples were run in
duplicate.
Data and statistical analyses
Data obtained from saturation binding experiments of
each subject were analysed by non-linear regression using
the GraphPad Prism™ software. The apparent equilibrium
dissociation constant (Kd) and the maximum density of
specific binding sites (Bmax) were obtained. Kd values were
normalized to log transformation before parametric ana-
lyses. All data were subjected to a Grubbs’s test in order to
detect and reject possible outlier values among experi-
mental groups. Pearson’s correlation r coefficient was
calculated to test for a possible association between
independent covariables (age, post-mortem interval and
storage time) and receptor density. When correlation was
significant, analysis of covariance was performed con-
trolling for the independent covariable. One-way analysis
of variance followed by Bonferroni’s post-hoc test was
used to compare results between radioligands. Results are
expressed as mean±standard deviation (SD) of individual
values.
Statistical comparisons between groups were conducted
by non-linear curve-fitting coanalysis of all individual
binding experiments. The selection between a single-
curve model (absence of differences between groups) and
a two-curve model (statistical differences between groups)
was made by the extrasum-of-squares F test using
GraphPad Prism™. When statistical differences between
curves were obtained, further individual contrasts were
performed to detect whether differences were attributable
to changes in Bmax and/or Kd values between groups
32,33.
The analysis that permitted one or more of the para-
meters to be shared without a significant increase in the
residual variance was taken as the best fit. In this non-
linear analysis, results (Bmax and Kd) are expressed as the
best estimation parameter ± SD. These values obtained
from simultaneous non-linear regression analyses were
not used for parametric statistical calculations.
In all analyses, the level of statistical two-tailed sig-
nificance was chosen as p= 0.05.
Results
Specific binding sites for [18F]altanserin, [3H]LSD and [3H]
MDL100907
The individual non-linear analysis of each radioligand
binding fitted to a saturation curve displaying a single
specific binding site of high affinity, compatible with
selective detection of 5-HT2ARs. The receptor density
(Bmax) in the overall population was similar when iden-
tified by [18F]altanserin or [3H]MDL100907 binding, while
it was significantly higher when estimated by [3H]LSD
binding (192 ± 82% over [18F]altanserin, p < 0.01; 210 ±
89% over [3H]MDL100907, p < 0.0001). The binding
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affinities, expressed by Kd values, were always in the
nanomolar range (Kd= 0.36 ± 0.19 nM for [
18F]altanserin;
Kd= 1.26 ± 0.86 nM for [
3H]LSD; Kd= 0.47 ± 0.37 nM for
[3H]MDL100907) without significant differences between
radioligands.
Positive correlations between densities obtained with
[18F]altanserin and [3H]MDL100907 (r= 0.332, p < 0.05),
and between [3H]MDL100907 and [3H]LSD (r= 0.894,
p < 0.0001) were found. In contrast, no significant corre-
lation was found between densities obtained with [18F]
altanserin and [3H]LSD, suggesting that these radi-
oligands could identify different binding populations.
Effects of demographic parameters and post-mortem
conditions
The density of [18F]altanserin binding sites displayed a
negative correlation with the age at death (r=−0.341;
p < 0.05). According to this linear decay, the average
decrease per decade for 5-HT2ARs was 35 ± 15 fmol/mg.
In the case of [3H]MDL100907 binding, there was also a
decrease of density with age (30 ± 17 fmol/mg per decade)
that did not reach significant correlation (r=−0.283; p=
0.08). No correlation between age at death and density of
[3H]LSD binding sites was obtained.
[18F]altanserin, [3H]LSD and [3H]MDL100907 binding
properties were not significantly affected neither by post-
mortem interval nor by storage time at −80 °C.
Comparison between schizophrenia and control groups
The co-analysis of saturation curves obtained with [18F]
altanserin showed a statistically significant reduction of the
density of the binding sites in the schizophrenia group
compared to matched controls. No differences in affinity
were detected between schizophrenia and control groups
(Table 1). When the presence of antipsychotic drugs was
considered, the co-analysis demonstrated a significant
reduction of [18F]altanserin binding sites in antipsychotic-
free subjects with schizophrenia (Bmax= 329 ± 24 fmol/mg)
vs. matched controls (Bmax= 410 ± 25 fmol/mg) (p < 0.05)
(Fig. 3A). In contrast, subjects with schizophrenia and
presence of antipsychotic treatment displayed density values
(Bmax= 376 ± 18 fmol/mg) closer to the respective matched
control group (Bmax= 411 ± 23 fmol/mg) (Fig. 3A). No
changes were observed in the affinity parameters (Kd=
0.30 ± 0.07 nM in antipsychotic-free schizophrenia group
vs. Kd= 0.34 ± 0.07 nM in matched controls; Kd= 0.33 ±
0.05 nM in antipsychotic-treated schizophrenia group vs.
Kd= 0.29 ± 0.06 nM in matched controls). As expected,
these findings were confirmed by analysis of covariance
controlling Bmax value for age.
The co-analysis of saturation curves obtained with [3H]
LSD demonstrated a significant increase of binding sites
in subjects with schizophrenia compared to matched
controls The co-analysis also demonstrated higher Kd
values of this radioligand in the schizophrenia group than
in controls (Table 1). When the presence of antipsychotic
drugs in blood was considered, the enhanced receptor
density was maintained in antipsychotic-free schizo-
phrenia subjects (Bmax= 791 ± 69 fmol/mg) when com-
pared with matched controls (Bmax= 646 ± 34 fmol/mg)
(p < 0.05) (Fig. 3B). Conversely, antipsychotic-treated
schizophrenia subjects displayed receptor density values
(Bmax= 735 ± 63 fmol/mg) that did not differ from those
in respective control group (Bmax= 635 ± 30 fmol/mg)
(Fig. 3B). In the case of Kd values, the increase was sig-
nificant for both antipsychotic-free (Kd= 1.45 ± 0.45 nM)
and antipsychotic-treated (Kd= 1.52 ± 0.44 nM) schizo-
phrenia subjects compared with respective controls (Kd=
0.69 ± 0.15 nM and Kd= 0.77 ± 0.15 nM) (p < 0.05). Re-
evaluation with age as covariate maintained similar
results. In order to test whether the residual presence of
antipsychotic drugs could contribute to the increased Kd
of [3H]LSD binding, a correlation between published Ki
for 5-HT2AR values34,35 of drugs detected in the post-
mortem toxicological screening and individual Kd values
obtained for [3H]LSD was performed. A significant
Table 1 Radioligand binding parameters in the prefrontal cortex of subjects with schizophrenia and matched controls.
Schizophrenia Control F[d.f.,d.f.] p Value
Bmax (fmol/mg) Kd (nM) n Bmax (fmol/mg) Kd (nM) n
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
[18F]Altanserin 352 ± 15 0.32 ± 0.05 20 410 ± 17 0.32 ± 0.05 20 F[1,288]= 6.361 0.0122
[3H]LSD 765 ± 47 1.5 ± 0.32 20 640 ± 23 0.73 ± 0.11 20 F[1,311]= 8.282 0.0043
[3H]MDL100907 324 ± 23 0.29 ± 0.07 20 335 ± 16 0.28 ± 0.04 20 F[1,294]= 0.354 0.7023
For each radioligand, the two sets of data (schizophrenia and control) were first analysed separately. The overall value for the sum of squares and the degrees of
freedom (d.f.) was the sum of the individual values of each fit. Next, the two sets of data were pooled and analysed simultaneously constraining them to share one or
two common parameters (Bmax, Kd). The pooled fit yielded values for the sum of squares and degrees of freedom. The analysis that permitted one or two parameters
to be shared without a significant increase in the residual variance was taken as the best fit. [18F]Altanserin and [3H]LSD binding curves were considered different
between schizophrenia and control. The subsequent analysis demonstrated that statistical differences were adscribed to different Bmax but not to Kd values. The F, d.f.
and p values displayed correspond to this condition. For [3H]MDL100907, estimations obtained under equivalent analysis are shown.
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correlation (r= 0.68, p= 0.04) was obtained in
antipsychotic-treated subjects.
The co-analysis of curves obtained with [3H]
MDL100907 showed no differences of binding sites
between subjects with schizophrenia and matched con-
trols. The affinities were also similar (Table 1). No dif-
ferences were detected neither in antipsychotic-free
schizophrenia subjects (Bmax= 324 ± 37 fmol/mg; Kd=
0.34 ± 0.13 nM) with respective controls (Bmax= 328 ±
23 fmol/mg; Kd= 0.32 ± 0.07 nM) nor in antipsychotic-
treated subjects (Bmax= 330 ± 28 fmol/mg; Kd= 0.26 ±
0.07 nM) vs. matched controls (Bmax= 344 ± 22 fmol/mg;
Kd= 0.25 ± 0.05 nM) (Fig. 3C). Age at death did not
influence the results in the analysis of covariance.
Discussion
The present study demonstrates in post-mortem human
frontal cortex that alterations of 5-HT2ARs observed in
schizophrenia are dependent on the pharmacological
properties of the radiotracer used to identify this receptor.
Thus, binding assays with an agonist ([3H]LSD), an
antagonist ([3H]MDL100907) and an inverse agonist
([18F]altanserin) radiotracer conducted in similar incuba-
tion conditions from identical samples lead to different
results. The present study provides evidence that the
agonist radioligand binding to 5-HT2ARs is increased in
schizophrenia, whereas inverse agonist radioligand bind-
ing is reduced, and the antagonist radioligand binding
remains unaltered. This differential pattern is remarkable
in antipsychotic-free subjects, whereas the presence of
these drugs in blood tends to reverse the 5-HT2AR density
alterations to control values. Until recently, an equivalent
PET study was not feasible, mainly due to the lack of
suitable agonist radiotracers for selective 5-HT2AR iden-
tification36. However, the recent development of [11C]
Cimbi-3615,18, a non-selective 5-HT2A/B/CR agonist
37,
could help to confirm through head-to-head in vivo
comparisons between antagonist and inverse agonist
radiotracers the findings here reported in the post-
mortem tissue. Nevertheless, the technical and ethical
feasibility of in vivo identification of 5-HT2ARs by three
different PET radiotracers in the same patient and short
time frame is limited. Therefore, in vitro post-mortem
studies could help to overcome these drawbacks in the
study of neurotransmitter receptor molecular alterations.
However, other potentially confounding factors, especially
the existence of previous treatment with antipsychotic
drugs, add limitations to the conclusions of post mortem
studies. In fact, the number of antipsychotic-free subjects
included in this type of studies is very limited38 (Supple-
mentary Table S1).
The increased density of 5-HT2ARs identified by the
agonist radiotracer [3H]LSD confirms the proposed higher







































































Fig. 3 Alterations of 5-HT2A receptor density in schizophrenia.
Saturation curves of the specific [18F]altanserin (A), [3H]LSD (B) and
[3H]MDL100907 (C) binding to membranes of post-mortem frontal
cortex from subjects with schizophrenia and presence of antipsychotic
drugs in the blood at the time of death (antipsychotic-treated),
subjects with schizophrenia and no antipsychotic drugs in the blood
(antipsychotic-free), and matched control subjects. Each schizophrenia
group was analysed vs. the respective control group, but in order to
clarify, here the two control groups are shown together. The curves
represent the best-fit estimation generated by the non-linear co-
analysis of individual results in each group. The density of 5-HT2ARs is
expressed as the asymptote value (Bmax) of the radioligand bound.
The affinity of the radioligand is expressed by the concentration of
radioligand that promotes the half-maximal bound (Kd). Points
representing means were not used for statistical analysis.
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Previous studies with the partial agonist radioligand [3H]
ketanserin have reported similar findings in antipsychotic-
free subjects13,24. Endogenous and exogenous agonists
bind preferentially to the high-affinity state of the receptor,
which represents the active functional conformation cou-
pled to cell signalling pathways (Fig. 1). Recently, the
assessment of 5-HT2AR coupling to G proteins in post-
mortem frontal cortex has demonstrated an enhanced
sensitivity of inhibitory Gi1 proteins in response to the
agonist (±)DOI (2,5-dimethoxy-4-iodoamphetamine) in
schizophrenia20. In concordance, the prolactin response to
the 5-HT-releasing drug D-fenfluramine39, which is con-
sidered a functional in vivo test dependent on 5-HT2A/CRs
activation, is enhanced in drug-free schizophrenia sub-
jects40,41. Therefore, evidence points towards a functional
hyperactivity of 5-HT2ARs in schizophrenia. This issue has
resulted in controversy since PET studies with [18F]altan-
serin have suggested decreased binding potential in
antipsychotic-naive schizophrenia patients5,6. The present
study illustrates how the reduction of [18F]altanserin
binding (−20%) is compatible with enhanced binding
(+22%) of agonist radiotracers as [3H]ketanserin and [3H]
LSD. The compound altanserin has been classically
regarded as the selective 5-HT2AR antagonist. However, in
the brain cortex, this drug shows inverse agonist proper-
ties13,21, which means preferential labelling to the receptor
conformation uncoupled from G proteins. In this way, the
pharmacological profile of [18F]altanserin explains the
reduced 5-HT2AR density reported in schizophrenia as a
reduction of the uncoupled conformation of this receptor.
G-protein-coupled (higher affinity for agonists than for
inverse agonists) and G-protein-uncoupled (higher affinity
for inverse agonists than for agonists) receptor con-
formations are interchangeable molecular states of GPCRs.
In brains of subjects with schizophrenia, the imbalance
between 5-HT2AR conformations in favour of the G-
protein-coupled state would be expressed as increased
density of the agonist [3H]LSD binding and reduced
density of the inverse agonist [18F]altanserin binding, as
observed in the present study (Fig. 2). Moreover, this
hypothesis should be supported by the concurrent absence
of changes in the 5-HT2AR density delineated by selective
antagonist radiotracers. Neutral antagonist drugs do not
distinguish among molecular conformations of the recep-
tor and, thereby, are not suitable tools to detect the exis-
tence of imbalance between 5-HT2AR conformational
states in schizophrenia. The absence of differences for the
antagonist [3H]MDL100907 binding between schizo-
phrenia and control groups obtained in the present study
agrees with this argument and supports the existence of a
functional 5-HT2AR imbalance in the pathophysiology of
the disorder. More recent post-mortem studies have added
further weight to this hypothesis by showing that mes-
senger RNA expression and total protein immunodetection
of 5-HT2ARs are unaltered in subjects with schizophrenia
free of antipsychotic treatment20.
One apparent inconsistency of the present study is the
different receptor binding density obtained between
radiotracers. [3H]LSD approximately identified a two-fold
higher number of binding sites than [18F]altanserin and
[3H]MDL100907. It is widely accepted that 5-HT2ARs are
assembled into homodimeric and heterodimeric struc-
tures24,42. Receptor oligomers coexist with monomeric
forms (Fig. 4). Dimeric receptor complex crosstalk to each
other promoting differential modulation of the ligand
access to the respective binding pockets36. In fact, the
binding of partial agonist and antagonists, as ketanserin
and MDL100907, to one of the two binding sites in the 5-
HT2AR homodimer introduces negative cooperativity
effects on the propensity of a second molecule of the same
drug to bind the dimer43. In contrast, the hallucinogenic
5-HT2AR agonist (±)DOB shows a similar affinity for the
two binding sites of the dimer43. Therefore, it is feasible to
propose that [3H]LSD is able to label the two binding sites
of the homodimeric 5-HT2AR, whereas [
3H]MDL100907,
[18F]altanserin and [3H]ketanserin binding to one of the
receptor pockets prevent the own radioligand binding to
the second site (Fig. 4). This molecular mechanism would
be reflected in a two-fold higher density when estimated
by radiotracers bound to the full homodimer with respect
to the density obtained by radiotracers bound only to one
of the monomers that conform to the dimer. The results
shown in the present study together with those in pre-
vious studies with the radiotracer [3H]ketanserin13,24
agree with this hypothesis of a homodimeric 5-HT2AR
structure and function. Certainly, the assumption of the
receptor oligomerization paradigm should affect future
comparisons between radiotracer binding properties.
The observed decline of 5-HT2AR density with ageing is
a repeated finding in previous post-mortem13,24,44 and
PET45 studies. This profound effect of ageing provides the
rationale for experimental designs based on one-to-one
individual matching of each schizophrenia case with
respective control, as performed here, rather than the
usual and less rigorous group-based matching.
The presence or absence at death of antipsychotic drugs
in the blood of subjects with schizophrenia represents
another relevant confounding factor in radioligand bind-
ing studies (Supplementary Table S1). In the present
study, the absence of antipsychotic drugs in the tox-
icological analysis does not mean that these subjects
termed as antipsychotic-free were antipsychotic-naive,
but rather that they were untreated in the nearest ante-
mortem period. The more [18F]altanserin binding and the
less [3H]LSD binding densities in antipsychotic-treated
respect to antipsychotic-free schizophrenia subjects sug-
gest that antipsychotic treatment would counterbalance
the 5-HT2ARs alterations observed in schizophrenia.
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Long-term treatment with second-generation anti-
psychotics modulates 5-HT2AR expression in animals
14,24
and could modify binding parameters due to residual
presence of antipsychotics acting as 5-HT2AR antago-
nists20. However, the possibility that observed alterations
of 5-HT2AR density (Bmax) in schizophrenia represent a
consequence of the current or past long-term anti-
psychotic treatment is improbable. First, the changes of
density are more evident in recent antipsychotic-free than
in antipsychotic-treated subjects. Second, the differential
up- or down-regulation of 5-HT2ARs associated with
recent antipsychotic treatment in function of the different
radiotracers makes unlikely a residual competitive effect
between the antipsychotic and the radioligand to bind the
receptor pocket. In contrast to density (Bmax), the
apparent affinity (Kd value) was sensitive to the residual
presence of antipsychotic drugs, although this effect was
only observed for [3H]LSD binding assays. The finding
reasserts the use of agonist radiotracers to better detect
the 5-HT2AR occupation by psychedelic drugs
46. Receptor
exploration in drug-free conditions is more feasible by
PET imaging than by retrospective post-mortem binding
studies. Indeed, most of the post-mortem studies evalu-
ating 5-HT2ARs in schizophrenia have been performed in
the brain of subjects under antipsychotic treatment, which
probably led to inconclusive results (Supplementary Table
S1). Besides this, when schizophrenia subjects were dif-
ferentiated between those under antipsychotic treatment
and those antipsychotic-free, the post-mortem radi-
oligand studies demonstrated up-regulation of brain
5-HT2ARs identified by agonist/partial agonist radio-
tracers13,20,23,24. Therefore, in order to discard eventual
bias in post-mortem studies, independent and well-
matched groups of antipsychotic-free and antipsychotic-
treated subjects should be selected and independently
analysed.
Another potential confounding factor to consider in the
present study is the fact that schizophrenia subjects died
mostly from violent suicide mechanisms. Suicide has been
proposed as a condition that could influence the evalua-
tion of 5-HT2ARs
47. However, there are several studies in
the frontal cortex of suicide victims with a variety of
psychiatric disorders supporting that suicide unlikely
represents a major confounder in 5-HT2AR binding
studies1,13,48,49.
In conclusion, the study and interpretation of 5-HT2AR
dysfunctions in schizophrenia requires a deep knowledge
of the pharmacological properties of the candidate
radiotracers. The distinction of 5-HT2AR radiotracers
between agonist, antagonist and inverse agonist may shed
light on the, up to now, contradictory results. According
to the different pharmacological profile, the present
results and most of the studies would demonstrate an
upregulation of the active functional 5-HT2AR con-
formation in the brain of subjects with schizophrenia.
The present results support the hypothesis that 5-
HT2AR molecular conformation and/or the receptor
interaction with other synaptic proteins might be altered
in schizophrenia. Moreover, as previously described, the
antipsychotic treatment seems also to modify the
[3H]LSD[3H]M100907
[18F]altanserin
Fig. 4 Monomer and oligomer conformations of the 5-HT2AR. The 5-HT2AR is expressed as single monomers but also as receptor complexes
constituted by two or more receptor units. The binding of a drug to one of the monomers of the complex could induce positive, negative or no
cooperativity for the binding to other monomers with the complex. For example, the binding of the antagonist MDL100907 or the inverse agonist
altanserin to one of the binding pockets of the homodimer introduces negative allosteric effects on the binding of the same drug to the second
binding pocket43. This negative cooperativity would prevent the identification of the total number of binding sites. In contrast, the binding of
hallucinogenic 5-HT2AR agonist such as (±)DOB and LSD to receptor homodimers does not modify the estimation of the total number of binding
sites43. Higher order 5-HT2AR oligomeric and heteromeric complexes of 5-HT2ARs with other GPCRs are also feasible
24,42.
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functional state of 5-HT2ARs, trying to revert the altera-
tions found in antipsychotic-free schizophrenia subjects.
Therefore, the development and in vivo use of agonist
radiotracers in antipsychotic-naive patients should be
encouraged to validate the 5-HT2AR overactivity here
proposed.
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